The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $1.28 / share. This is a decrease of ...

BofA raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $179 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...

In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and ...

CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...

H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following the Q4 report. The firm cites the company’s higher number ...

Diseases that are high priority for diagnostic improvement include relatively rare conditions that have high misdiagnosis rates such as spinal abscess. New research ...

CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) ...

A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95 ...